NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that the underwriters of its recently announced $2.2 billion public offering of common stock have exercised their over-allotment option.

The underwriters purchased nearly 3.9 million additional shares of Thermo Fisher's stock at $85.50 per share in exercising the over-allotment option.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.